Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: Implications for clinical practice and trial design

Guru Sonpavde, Gregory R. Pond, Stephanie Mullane, Angela Q. Qu, Giuseppe Di Lorenzo, Piera Federico, Andrea Necchi, Jonathan E. Rosenberg, Joaquim Bellmunt, Toni K. Choueiri

Research output: Contribution to journalArticle

Abstract

Abstract Background Taxanes such as paclitaxel and docetaxel are commonly used for second- or third-line salvage systemic therapy for metastatic UC. Although trials have generally excluded previous exposure to taxanes when using a taxane in a salvage therapy trial, taxanes might not be completely cross-resistant. Hence, we aimed to study outcomes with docetaxel after previous paclitaxel and the reverse sequence, to identify the level of cross-resistance between these taxanes. Patients and Methods Data from a randomized phase II trial that compared salvage therapy with docetaxel combined with either placebo or vandetanib for advanced UC were analyzed. Both arms were combined for analysis because no differences in any outcomes were observed. Data were also requested from institutions for patients who received paclitaxel after previous docetaxel treatment. Descriptive statistics were used to summarize patient and treatment characteristics and outcomes. The primary clinical end point of interest was overall survival (OS). Results Of 148 patients who received docetaxel with either vandetanib or placebo, 21 had received previous paclitaxel treatment. No difference in OS, progression-free survival, or response rate was observed with docetaxel based on previous paclitaxel treatment after adjusting for known prognostic factors. Among the 8 patients who received paclitaxel after previous docetaxel treatment, partial response was observed in 1 patient (12.5%) and stable disease in 2 patients (25%). Conclusion Docetaxel treatment after previous paclitaxel treatment and the reverse sequence demonstrates activity in advanced UC. There is no strong evidence to disallow patients with previous exposure to a taxane to enroll in a clinical trial involving another taxane.

Original languageEnglish
Article number335
Pages (from-to)250-256
Number of pages7
JournalClinical Genitourinary Cancer
Volume13
Issue number3
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

docetaxel
Taxoids
Paclitaxel
Clinical Trials
Carcinoma
Salvage Therapy
Therapeutics
Placebos
Survival
Disease-Free Survival

Keywords

  • Docetaxel
  • Paclitaxel
  • Prognosis
  • Salvage therapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Sonpavde, G., Pond, G. R., Mullane, S., Qu, A. Q., Di Lorenzo, G., Federico, P., ... Choueiri, T. K. (2015). Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: Implications for clinical practice and trial design. Clinical Genitourinary Cancer, 13(3), 250-256. [335]. https://doi.org/10.1016/j.clgc.2014.10.005

Incomplete cross-resistance between taxanes for advanced urothelial carcinoma : Implications for clinical practice and trial design. / Sonpavde, Guru; Pond, Gregory R.; Mullane, Stephanie; Qu, Angela Q.; Di Lorenzo, Giuseppe; Federico, Piera; Necchi, Andrea; Rosenberg, Jonathan E.; Bellmunt, Joaquim; Choueiri, Toni K.

In: Clinical Genitourinary Cancer, Vol. 13, No. 3, 335, 01.06.2015, p. 250-256.

Research output: Contribution to journalArticle

Sonpavde, G, Pond, GR, Mullane, S, Qu, AQ, Di Lorenzo, G, Federico, P, Necchi, A, Rosenberg, JE, Bellmunt, J & Choueiri, TK 2015, 'Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: Implications for clinical practice and trial design', Clinical Genitourinary Cancer, vol. 13, no. 3, 335, pp. 250-256. https://doi.org/10.1016/j.clgc.2014.10.005
Sonpavde, Guru ; Pond, Gregory R. ; Mullane, Stephanie ; Qu, Angela Q. ; Di Lorenzo, Giuseppe ; Federico, Piera ; Necchi, Andrea ; Rosenberg, Jonathan E. ; Bellmunt, Joaquim ; Choueiri, Toni K. / Incomplete cross-resistance between taxanes for advanced urothelial carcinoma : Implications for clinical practice and trial design. In: Clinical Genitourinary Cancer. 2015 ; Vol. 13, No. 3. pp. 250-256.
@article{4cccdf34d8d74da4928f1f6ad92c80cc,
title = "Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: Implications for clinical practice and trial design",
abstract = "Abstract Background Taxanes such as paclitaxel and docetaxel are commonly used for second- or third-line salvage systemic therapy for metastatic UC. Although trials have generally excluded previous exposure to taxanes when using a taxane in a salvage therapy trial, taxanes might not be completely cross-resistant. Hence, we aimed to study outcomes with docetaxel after previous paclitaxel and the reverse sequence, to identify the level of cross-resistance between these taxanes. Patients and Methods Data from a randomized phase II trial that compared salvage therapy with docetaxel combined with either placebo or vandetanib for advanced UC were analyzed. Both arms were combined for analysis because no differences in any outcomes were observed. Data were also requested from institutions for patients who received paclitaxel after previous docetaxel treatment. Descriptive statistics were used to summarize patient and treatment characteristics and outcomes. The primary clinical end point of interest was overall survival (OS). Results Of 148 patients who received docetaxel with either vandetanib or placebo, 21 had received previous paclitaxel treatment. No difference in OS, progression-free survival, or response rate was observed with docetaxel based on previous paclitaxel treatment after adjusting for known prognostic factors. Among the 8 patients who received paclitaxel after previous docetaxel treatment, partial response was observed in 1 patient (12.5{\%}) and stable disease in 2 patients (25{\%}). Conclusion Docetaxel treatment after previous paclitaxel treatment and the reverse sequence demonstrates activity in advanced UC. There is no strong evidence to disallow patients with previous exposure to a taxane to enroll in a clinical trial involving another taxane.",
keywords = "Docetaxel, Paclitaxel, Prognosis, Salvage therapy, Urothelial carcinoma",
author = "Guru Sonpavde and Pond, {Gregory R.} and Stephanie Mullane and Qu, {Angela Q.} and {Di Lorenzo}, Giuseppe and Piera Federico and Andrea Necchi and Rosenberg, {Jonathan E.} and Joaquim Bellmunt and Choueiri, {Toni K.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.clgc.2014.10.005",
language = "English",
volume = "13",
pages = "250--256",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Incomplete cross-resistance between taxanes for advanced urothelial carcinoma

T2 - Implications for clinical practice and trial design

AU - Sonpavde, Guru

AU - Pond, Gregory R.

AU - Mullane, Stephanie

AU - Qu, Angela Q.

AU - Di Lorenzo, Giuseppe

AU - Federico, Piera

AU - Necchi, Andrea

AU - Rosenberg, Jonathan E.

AU - Bellmunt, Joaquim

AU - Choueiri, Toni K.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Abstract Background Taxanes such as paclitaxel and docetaxel are commonly used for second- or third-line salvage systemic therapy for metastatic UC. Although trials have generally excluded previous exposure to taxanes when using a taxane in a salvage therapy trial, taxanes might not be completely cross-resistant. Hence, we aimed to study outcomes with docetaxel after previous paclitaxel and the reverse sequence, to identify the level of cross-resistance between these taxanes. Patients and Methods Data from a randomized phase II trial that compared salvage therapy with docetaxel combined with either placebo or vandetanib for advanced UC were analyzed. Both arms were combined for analysis because no differences in any outcomes were observed. Data were also requested from institutions for patients who received paclitaxel after previous docetaxel treatment. Descriptive statistics were used to summarize patient and treatment characteristics and outcomes. The primary clinical end point of interest was overall survival (OS). Results Of 148 patients who received docetaxel with either vandetanib or placebo, 21 had received previous paclitaxel treatment. No difference in OS, progression-free survival, or response rate was observed with docetaxel based on previous paclitaxel treatment after adjusting for known prognostic factors. Among the 8 patients who received paclitaxel after previous docetaxel treatment, partial response was observed in 1 patient (12.5%) and stable disease in 2 patients (25%). Conclusion Docetaxel treatment after previous paclitaxel treatment and the reverse sequence demonstrates activity in advanced UC. There is no strong evidence to disallow patients with previous exposure to a taxane to enroll in a clinical trial involving another taxane.

AB - Abstract Background Taxanes such as paclitaxel and docetaxel are commonly used for second- or third-line salvage systemic therapy for metastatic UC. Although trials have generally excluded previous exposure to taxanes when using a taxane in a salvage therapy trial, taxanes might not be completely cross-resistant. Hence, we aimed to study outcomes with docetaxel after previous paclitaxel and the reverse sequence, to identify the level of cross-resistance between these taxanes. Patients and Methods Data from a randomized phase II trial that compared salvage therapy with docetaxel combined with either placebo or vandetanib for advanced UC were analyzed. Both arms were combined for analysis because no differences in any outcomes were observed. Data were also requested from institutions for patients who received paclitaxel after previous docetaxel treatment. Descriptive statistics were used to summarize patient and treatment characteristics and outcomes. The primary clinical end point of interest was overall survival (OS). Results Of 148 patients who received docetaxel with either vandetanib or placebo, 21 had received previous paclitaxel treatment. No difference in OS, progression-free survival, or response rate was observed with docetaxel based on previous paclitaxel treatment after adjusting for known prognostic factors. Among the 8 patients who received paclitaxel after previous docetaxel treatment, partial response was observed in 1 patient (12.5%) and stable disease in 2 patients (25%). Conclusion Docetaxel treatment after previous paclitaxel treatment and the reverse sequence demonstrates activity in advanced UC. There is no strong evidence to disallow patients with previous exposure to a taxane to enroll in a clinical trial involving another taxane.

KW - Docetaxel

KW - Paclitaxel

KW - Prognosis

KW - Salvage therapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84929077299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929077299&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.10.005

DO - 10.1016/j.clgc.2014.10.005

M3 - Article

C2 - 25481485

AN - SCOPUS:84929077299

VL - 13

SP - 250

EP - 256

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

M1 - 335

ER -